Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of paclitaxel in preparation of medicament for treatment of EGFR-TKI acquired resistance

An EGFR-TKI, acquired technology, applied in the field of application of paclitaxel in the preparation of drugs for the treatment of EGFR-TKI acquired drug resistance

Inactive Publication Date: 2012-08-08
JIANGSU PROVINCE HOSPITAL
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] So far, there is no particularly effective solution to the problem of acquired resistance to EGFR-TKIs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of paclitaxel in preparation of medicament for treatment of EGFR-TKI acquired resistance
  • Application of paclitaxel in preparation of medicament for treatment of EGFR-TKI acquired resistance
  • Application of paclitaxel in preparation of medicament for treatment of EGFR-TKI acquired resistance

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] 1. Cell culture: H1975 cells are EGFR L858R-T790M mutant and are resistant to EGFR-TKI; H820 cells have MET amplification and are resistant to EGFR-TKI; A549 cells express wild-type EGFR gene and are resistant to EGFR-TKI; PC- 9 lines of EGFR-TKI highly sensitive cells, the above-mentioned H1975, H820, and PC-9 cells were purchased from ATCC (USA), and A549 cells were stored in our laboratory. Cell culture uses RPMI-1640 medium (containing 10% FBS, glutamine and penicillin) to subculture cell lines H1975, H820, A549, PC-9. Cell culture was performed in an incubator containing 5% CO2 at 37°C, and the culture medium was replaced every 1 to 2 days. The four types of cells are adherent cells. When the cells grow to a confluency of about 90%, they are digested with trypsin, and repeatedly pipetted to leave the bottom wall of the culture flask, and then collected by centrifugation. Half of the collected cells are used for RNA extraction and half for protein extraction.

[001...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of paclitaxel in preparation of medicament for treatment of non small cell lung cancer EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitor) resistance. Lung cancer ranks the first in cancer incidence and mortality all over the world. Curative effects of Gefitinib and Erlotinib in NSCLC are often limited by acquired resistance, and currently known main mechanism of acquired resistance is due to mutation of second generation of EGFRT790M and acquired amplification of MET gene. The invention shows that when EGFR-TKI acquired resistance appears, paclitaxel may reverse the resistance. That is to say, non small cell lung cancer patients who generate acquired resistance from Erlotinib / Gefitinib treatment can reconsider the use of Erlotinib / Gefitinib treatment after chemotherapy with paclitaxel, so as to make the erlotinib / gefitinib continue to function; meanwhile, paclitaxel may also inhibit tumor, and thus play rotary resistance and synergism.

Description

technical field [0001] The invention relates to the application of paclitaxel in the preparation of EGFR-TKI drug resistance medicine for treating non-small cell lung cancer. Background technique [0002] At present, acquired drug resistance in the process of tumor drug treatment has become a worldwide problem, and it is also the reason why the treatment of tumors is ineffective. EGFR-TKI drugs (erlotinib or gefitinib) are very important targeted drugs in the treatment of advanced non-small cell lung cancer, but the emergence of acquired drug resistance limits their clinical application, so it is necessary to actively explore acquired Mechanisms of drug resistance. The mechanism of acquired resistance to EGFR-TKI drugs is still not fully understood. Existing studies have shown that the generation of acquired resistance to EGFR-TKIs may be mainly related to the following two mechanisms: secondary exon T790M mutation and secondary amplification of MET. At present, the resea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/337A61P35/00
Inventor 郭人花束永前金时代王萱怡
Owner JIANGSU PROVINCE HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com